INTRODUCTION {#em22196-sec-0001}
============

Global interest in the use of transcriptional profiling for risk assessment has led to the development of new high‐throughput analytical approaches to assess dose‐response \[Yang et al., [2007](#em22196-bib-0036){ref-type="ref"}; Kuo et al., [2016](#em22196-bib-0022){ref-type="ref"}\]. However, although substantial amounts of transcriptional data have been generated in the UVR field, the data have been predominantly used to support an understanding of mechanistic effects. These studies have shown that UVR exposure (particularly in the UVB spectrum) can induce changes in gene expression and pathways associated with adverse health effects \[Becker et al., [2001](#em22196-bib-0002){ref-type="ref"}; Li et al., [2001](#em22196-bib-0023){ref-type="ref"}; Murakami et al., [2001](#em22196-bib-0027){ref-type="ref"}; Sesto et al., [2002](#em22196-bib-0029){ref-type="ref"}; Takao et al., [2002](#em22196-bib-0032){ref-type="ref"}; Enk et al., [2004](#em22196-bib-0012){ref-type="ref"}\]. Most in vitro studies have also shown that UV exposure can induce apoptosis in cells and cause a strong and persistent induction in the expression of oncogenes such as c‐myc and c‐jun \[He et al., [2004](#em22196-bib-0014){ref-type="ref"}\]. Similarly, studies using solar‐simulated UVR exposure have demonstrated differential gene expression associated with apoptosis, cell growth arrest, and cytokines \[Marrot et al., [2005](#em22196-bib-0024){ref-type="ref"}, [2010](#em22196-bib-0025){ref-type="ref"}; Kaneko et al., [2008](#em22196-bib-0019){ref-type="ref"}\]. However, translating lists of time‐ and dose‐dependent differentially expressed genes into meaningful information to support risk assessment has remained a challenge.

Over the past decade, software has been developed to analyze genomic data to derive benchmark doses (BMDs) of effects \[Yang et al., [2007](#em22196-bib-0036){ref-type="ref"}\]. BMD modeling was first developed by Crump \[[1984](#em22196-bib-0009){ref-type="ref"}\] and is now being applied by the US Environmental Protection Agency \[US EPA, [2012](#em22196-bib-0034){ref-type="ref"}\] for conventional risk assessment. A BMD represents the dose at which a predefined increase above background (in most applications selected as 10% or one standard deviation \[Slob, [2017](#em22196-bib-0030){ref-type="ref"}\]) occurs in a dose‐response experiment for the endpoint under investigation. A variety of mathematical models are applied, and the model that best fits the data is selected to identify the BMD \[Yang et al., [2007](#em22196-bib-0036){ref-type="ref"}; US EPA, [2012](#em22196-bib-0034){ref-type="ref"}\]. This approach is preferred over the selection of a no (or lowest) observed effects level because it is not tied to the selection of a dose used in the experiment (rather it extrapolates the predefined response from the curve). BMD modeling of global transcriptomic data can be done in a high‐throughput manner through the use of the BMDExpress software \[Yang et al., [2007](#em22196-bib-0036){ref-type="ref"}\]. This package allows the user to model and apply filters to derive both individual gene and pathway (or other gene groups) BMDs. Pathway BMDs are generally represented as the mean or median BMD of responding genes within a pathway, with some criteria applied (e.g., significant enrichment of this pathway or a minimum number of genes that yield BMDs within the pathway). The approach has been widely applied in chemical toxicology and case studies have shown a high degree of correlation between gene/pathway BMDs and BMDs for conventional endpoints \[e.g., Bhat et al., [2013](#em22196-bib-0003){ref-type="ref"}; Jackson et al., [2014](#em22196-bib-0018){ref-type="ref"}; Dean et al., [2017](#em22196-bib-0010){ref-type="ref"}; Farmahin et al., [2017](#em22196-bib-0013){ref-type="ref"}\]. Thus, transcriptional BMDs have been proposed as points of departure for use in human health risk assessment \[Thomas et al., [2013](#em22196-bib-0033){ref-type="ref"}; Moffat et al., [2015](#em22196-bib-0026){ref-type="ref"}\].

Recently, by using case examples in the ionizing radiation field, we have shown the possibility of using BMDs as thresholds of effects for genes and pathways that are well established radiation responders (e.g., p53, cell cycle regulation, and so forth) \[Chauhan et al., [2016](#em22196-bib-0008){ref-type="ref"}\]. Indeed, we posit that BMD modeling of transcriptional datasets provides an opportunity to provide relevant mechanistic and quantitative information on the dose‐response relationship to support decision‐making in the field of ionizing radiation following further targeted validation studies.

To explore this application in more detail, in this study we performed BMD modeling on transcription response data from human‐derived skin cells exposed to solar‐simulated UVR. Human keratinocytes were exposed to solar‐simulated UVR at three environmentally‐relevant doses, and cells were harvested following a 6‐ or 24 hr incubation period. Global gene expression profiling was performed using Illumina microarray technology. Statistically significant expressed gene probes, as assessed by one‐way analysis of variance (ANOVA), were subjected to BMD modeling. BMD based values for genes and pathways were derived and a quantitative threshold, based on the median distribution of these genes, was obtained for solar‐simulated UVR‐exposed cells.

MATERIALS AND METHODS {#em22196-sec-0002}
=====================

Materials {#em22196-sec-0003}
---------

All solutions were prepared with 18 MΩ water (Milli‐Q plus PF unit, Millipore Corp., Bedford, MA). Cells were detached from the culture dishes by trypsinization (Trypsin/EDTA, Cascade Biologics), followed by neutralization (Trypsin Neutralizer, Cascade Biologics).

Cell Maintenance {#em22196-sec-0004}
----------------

Neonatal epidermal keratinocytes (HEKn, cat \# C‐001‐5C) were purchased from Cascade Biologics (Portland, OR), and cultured at 37°C (5% CO~2~) in complete medium \[EpiLife^®^ basal medium supplemented with calcium chloride, PSA solution, and HKGD growth kit (Cascade Biologics)\]. About 7.5 × 10^4^ cells were transferred into each 60 mm^2^ dishes containing 5 mL of complete media and cultured until 60--70% confluence. Prior to irradiation in the solar simulator the cells were washed once with sterile phosphate buffered saline (PBS) pH 7.4, and covered with a layer of PBS (5 mL) to prevent drying.

Ultraviolet‐Radiation Exposure {#em22196-sec-0005}
------------------------------

Solar simulated UVR exposure was performed using an in‐house Oriel solar simulator (Stratford, CT) equipped with a 1,600 W Xenon short arc lamp with an Oriel Air Mass 1 Direct Filter, (AM1:D:B; model 81074), calibrated to mimic a typical summer solar irradiance in Ottawa, Ontario, Canada (latitude 45°25′N). A KG2 Short Pass Filter was also placed between the cell culture and the source to limit excessive infrared transmission. The average spectral irradiance over an area of 17 × 17 cm was found to be 9.84 mW/cm^2^ for UVA (98.3%), 0.174 mW/cm^2^ for UVB (1.7%), and 10 mW/cm^2^ (0.017 mW/cm^2^ erythemally‐weighted) for the total UVR irradiance at an emission rate of 0.1 kJ/m^2^·sec, which was determined using a spectroradiometer (Optronics Laboratories, Model 754‐C) and integrating the area under the curve between 280 and 400 nm. For comparison, the solar irradiance measured in Ottawa on July 14, 2011 at 11:15 am was 5.30 mW/cm^2^ for UVA (95.5%), 0.252 mW/cm^2^ for UVB (4.5%), and 5.55 mW/cm^2^ (0.019 mW/cm^2^, erythemally‐weighted) for the total UVR irradiance. Keratinocyte cultures grown in 60 mm petri dishes were placed 186 mm from the solar simulator lamp where they received a dose of either 0, 10, 20, or 150 kJ/m^2^ of unweighted UVR and were maintained at 37°C using a temperature‐controlled water bath and a customized water circulation system. The UVR doses used in this study were based upon UVR doses applied in a separate study and were therefore not ideal for a proper BMD analysis; however these results still demonstrate the promise of BMD modeling to assessing point‐of‐departure of genes/pathways in response to UVR. The erythemally‐weighted equivalence of the unweighted dose is displayed in the following table (Table [1](#em22196-tbl-0001){ref-type="table"}).

###### 

Treatment Dose and its Erythemally‐Weighted Equivalence

  Unweighted UVR dose             CIE[a](#em22196-note-0001){ref-type="fn"}‐erythema weighted UV dose (kJ/m^2^)   Minimal erythemal dose
  ------------------------------- ------------------------------------------------------------------------------- ------------------------
  (kJ/m^2^)                       (kJ/m^2^)                                                                       (MED)
  0                               0                                                                               0
  10                              0.017                                                                           0.068
  20                              0.034                                                                           0.14
  150                             0.2545                                                                          1.01
  1 MED = 0.25 kJ/m^2^ weighted                                                                                   

ISO 17166:1999/CIE S007‐1998.

The CIE‐erythema weighted UV dose, also known as the effective dose or erythemal dose, is calculated with the erythemal effective irradiance (*E* ~eff~) as a function of exposure time of *t* seconds. $$\text{CIE}‐\text{erythema}~\text{weighted}~\text{UV}~\text{dose}~\left( {J/\text{cm}^{2}} \right)\, = E_{\text{eff}} \ast \, t.\text{where}~1~J/\text{cm}^{2}{\, = \,}10~\text{kJ}/m^{2}.$$

The erythemal effective irradiance (*E* ~eff~) from a source of ultraviolet radiation is obtained by weighting the spectral irradiance of the radiation at wavelength *λ* in nm by the effectiveness of radiation of this wavelength to cause a minimal erythema and summing over all wavelengths (250--400 nm) present in the source spectrum and is defined by the equation: $$E_{\text{eff}} = \,\Sigma~E_{\lambda} \ast \, S_{\lambda}$$where *E~λ~* is the spectral irradiance in W⋅m^−2^ ⋅ nm^−1^ and *S*(*λ*) is the weighting factor determined in accordance with the CIE‐erythema reference action spectrum.

Following exposure to sham or solar‐simulated UVR, cultures were placed back into a 37°C incubator and were harvested 6‐ or 24 hr postexposure for RNA isolation. The sham samples were handled identically and concurrently with UVR‐treated samples, but they received no UVR exposure. A total of six independent experiments were conducted, with each experiment containing samples exposed to a sham‐control and three doses of UVR for each time point (6‐ or 24 hr).

RNA Extraction/Hybridization {#em22196-sec-0006}
----------------------------

Following treatment, keratinocytes within 60 mm culture dishes were washed with PBS and replaced with Qiagen\'s RLT lysis buffer containing 2‐Mercaptoethanol (Qiagen) and immediately frozen in a −80°C freezer. Frozen lysates were later thawed and pipetted onto a QIAshredder spin column, and total RNA was extracted using RNeasy Mini kits according to the manufacturer\'s instructions (Qiagen). During the procedure, Qiagen\'s On‐Column RNase‐free DNase was used to eliminate possible DNA contamination. RNA concentration was evaluated using a NanoDrop 2000 spectrophotometer (ThermoScientific) and RNA integrity was confirmed using an Agilent 2100 Bioanalyzer with RNA 6000 PicoChip kits (Agilent Technologies), following the manufacturer\'s instructions (Agilent Technologies, Mississauga, ON). Only high quality RNA (OD 260/280 ≥ 1.8, RIN ≥ 7.0) was used for analysis of differential gene expression.

Total RNA (150 ng) from each sample was used to generate biotin‐labeled cRNA following the Illumina TotalPrep 96 RNA Amplification Kit (Ambion). Agilent\'s Low RNA Input Fluorescent Linear Amplification Kit was used to generate fluorescently‐labeled cRNA, from the total RNA, following the manufacturer\'s protocol (Agilent Technologies, Mississauga, ON). The mRNA from the total RNA was primed with the (d)T‐T7 primer and amplified using MMLV‐reverse transcriptase into (5′to 3′) cDNA. Cyanine‐3 labeled (3′ to 5′) cRNA was generated from the cDNA, using T7 RNA polymerase and isolated using the Qiagen\'s RNeasy Mini kit following the manufacturer\'s protocol (Qiagen).

For each sample, 1.5 μg of biotin‐labeled cRNA was hybridized onto Illumina Human HT‐12 V3.0 expression BeadChips (human3) (Illumina), according to the manufacturer\'s instructions. The Illumina BeadChips were imaged and quantified with the Illumina iScan scanner (Illumina) and data were processed with Illumina GenomeStudio v2010.2 software. Data processing included averaging signal intensities for each beadtype, quantile normalization, and log~2~‐transformation. All expression values were first log~2~ transformed to minimize skews in the data and provides more realistic variation measures. Quantile normalization was applied to impose the same empirical distribution across all the samples \[Bolstad et al., [2003](#em22196-bib-0004){ref-type="ref"}\]. Briefly, a reference array of empirical quantiles is first computed by taking the average across all ordered samples. The original expression values are then replaced by the entries of the reference array with the same rank.

BMD Modeling {#em22196-sec-0007}
------------

Datasets were normalized and genes were modeled and imported into BMDExpress (version 1.41) software \[Yang et al., [2007](#em22196-bib-0036){ref-type="ref"}\]. A built‐in one‐way analysis of variance (ANOVA) test with *P*‐value ≤ 0.05 was used to determine differentially expressed genes as recommended by Webster et al. \[[2015](#em22196-bib-0035){ref-type="ref"}\]. Thereafter, gene probes exhibiting a significant change in expression in at least one dose point were modeled using all available best‐fit models (which included the Hill, Power, Linear, and 2° Polynomial models) to identify potential dose‐response relationships. For each dataset of statistically significant gene probe expressions, the maximum degree of polynomial models applied was dependent upon the number of radiation doses (excluding control) minus one. A best‐fit model was selected based on the following criteria: First, a nested chi‐square test was performed with a cutoff of 0.05 to choose between Linear and Polynomial models. Next, between the Hill, Power, Linear and Polynomial models, the least complex model was selected with the lowest Akaike Information Criterion (AIC). Finally, a best‐fit model needed to have a goodness‐of‐fit *P*‐value ≥ 0.1. A Hill model was flagged if the *k* parameter of the model was less than one‐third of the lowest positive dose. In the case where a flagged Hill model was selected as the best‐fit model based on the above criteria, the next best model with goodness‐of‐fit *P*‐value ≥ 0.05 was selected. In the case where the next best model with *P*‐value ≥ 0.05 was not available, the flagged Hill model was retained and modified to 0.5 of the lowest nonflagged Hill BMD value. Other parameters for modeling included power restricted to 1, maximum iterations of 250, confidence interval of 0.95, and benchmark response value of 1.349, which approximates a 10% change and is the default value in BMDExpress software \[Yang et al., [2007](#em22196-bib-0036){ref-type="ref"}\] as defined in Thomas et al., [2007](#em22196-bib-0039){ref-type="ref"}.

Using the built‐in Defined Category Analysis feature of BMDExpress, the remaining probes that demonstrated dose‐response characteristics, that passed the selection criteria described above, were mapped to Ingenuity Pathway Analysis (downloaded on December 15, 2015). Probes annotated to more than one gene (promiscuous probes) were removed from further analysis, as were probes yielding BMD values higher than the highest dose and a goodness‐of‐fit *P*‐value ≤ 0.1. Only probes that met the data acceptance criteria were retained.

BMDExpress Data Viewer Parameters {#em22196-sec-0008}
---------------------------------

Export files from BMDExpress were uploaded to BMDExpress Data Viewer \[Kuo et al., [2016](#em22196-bib-0022){ref-type="ref"}\] for visualization of gene BMD, pathway BMD mean/median, and model distributions. Dataset Exploratory Tools, including Functional Enrichment Analysis and Multiple Dataset Comparison were used for data analyzes. For each dataset the default settings provided by the software were applied. This included the removal of genes with BMD/BMDL (lower 95% confidence limit) ratio ≥ 2. Lastly, BMDExpress Data Viewer determined the appropriate bin sizes using Google Chart\'s histogram implementation.

RESULTS {#em22196-sec-0009}
=======

Probe Modeling {#em22196-sec-0010}
--------------

A graphical representation to illustrate the distribution of best‐fit models generated by BMDExpress software for statistically significant ANOVA filtered dose‐responsive probes, for the 6 hr and 24 hr time‐points are depicted in Figure [1](#em22196-fig-0001){ref-type="fig"}. A large portion of the probes fit a linear model (46.7% for 6 hr and 41.3% for 24 hr) (Fig. [1](#em22196-fig-0001){ref-type="fig"}A, Table [2](#em22196-tbl-0002){ref-type="table"}). As illustrated in Figure [1](#em22196-fig-0001){ref-type="fig"}B, the BMD histogram of filtered probe data demonstrated two distinct modes of response, with Mode 1 ranging from 0 to 27 kJ/m^2^ and Mode 2 ranging from 38 to 150 kJ/m^2^. Pathway analysis of the probes comprising each mode was conducted for the 6 hr time‐point (Table [3](#em22196-tbl-0003){ref-type="table"}). In general, Mode 1 comprised pathways involved in cell signaling and DNA damage response, while pathways in Mode 2 shared similar responses but were also broadly associated with immune response and developmental processes such as cancer. The 24 hr time‐point yielded similar pathways, but with a lower percentage of mapped genes (Supporting Information Table S1). The median BMD values of each mode was found to be ∼16 kJ/m^2^ for Mode 1 and ∼108 kJ/m^2^ for Mode 2 at both time‐points (Table [2](#em22196-tbl-0002){ref-type="table"}). The median distribution across all probes was 94.4 kJ/m^2^ for the 6 hr time‐point and 101.9 kJ/m^2^ for the 24 hr time‐point (Table [2](#em22196-tbl-0002){ref-type="table"}).

![BMD summary outputs (A) 6 and 24 hr pie charts plotted to illustrate the distribution of best‐fit models selected by BMDExpress for the statistically significant UV‐responsive gene probes (B) BMD probe distribution (C) BMD median pathway distribution.](EM-59-502-g001){#em22196-fig-0001}

###### 

BMD Summary Statistics

  Time‐point   BMD probe median   Mode 1 BMD Median   Mode 2 BMD Median   BMD pathway median   Best‐fit
  ------------ ------------------ ------------------- ------------------- -------------------- ----------
  6            94.41              17.97               105.63              83.37                linear
  24           101.94             15.86               111.17              80.25                linear

###### 

BMD Pathway Modal Analysis for 6 hr Post Irradiation

  Mode 1 (dose: 0--27 kJ/m^2^)                                                     *P* value     Genes
  -------------------------------------------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------
  Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis   2.57 E --02   MAPK1,PIK3R1,CREBBP,WNT2B,CSNK1A1,VEGFC,IKBKE,JAK2,IRAK3,PDGFB,PRKCZ,NLK,CREB1,CHUK,TRAF5,RYK,IRAK2
  Chronic myeloid leukemia signaling                                               5.37 E --03   CDKN2A,E2F4,HDAC4,MAPK1,PIK3R1,CTBP2,IKBKE,CHUK,CBLC
  Xenobiotic metabolism signaling                                                  1.02 E --02   HDAC4,MAPK1,PPP2R2A,PIK3R1,CREBBP,HS2ST1,GSTT1,PRKCZ,GSTT2/GSTT2B,ALDH3A2,SULT1A1,NCOA1,CHST11,PPP2R5C,HS3ST1,UGT2B11,SCAND1
  Protein ubiquitination pathway                                                   3.72 E --02   PSMA6,UBE2Q1,HLA‐A,PSMC4,ANAPC10,UBE4A,SKP2,UBE2D4,UBE2D2,PSMB2,PSMD12,HSPB11,ANAPC11,PSMC3,UBE2C
  iNOS signaling                                                                   7.24 E --04   MAPK1,CREBBP,IKBKE,CHUK,JAK2,IRAK3,IRAK2
  RAR activation                                                                   6.92 E --03   CSNK2A1,ARID1A,MAPK1,PIK3R1,CDK7,CREBBP,GTF2H2,JAK2,PRKCZ,TRIM24,BRD7,PRKAR1B,NCOA1,SCAND1
  PI3K/AKT signaling                                                               1.05 E --02   MAPK1,INPP5F,GAB1,PPP2R2A,PIK3R1,IKBKE,PPP2R5C,CHUK,JAK2,PRKCZ
  Cyclins and cell cycle regulation                                                1.95 E --02   CDKN2A,E2F4,HDAC4,PPP2R2A,CDK7,PPP2R5C,SKP2
  Mitotic roles of polo‐like kinase                                                6.76 E --03   PLK4,PPP2R2A,ANAPC10,PKMYT1,PLK1,PPP2R5C,ANAPC11
  IGF‐1 signaling                                                                  7.08 E --03   IGFBP6,CSNK2A1,CASP9,MAPK1,PIK3R1,PRKAR1B,JAK2,SOCS5,PRKCZ
  HIPPO signaling                                                                  1.05 E --02   CSNK1E,DLG5,PPP2R2A,FRMD6,PPP2R5C,STK3,PRKCZ,SKP2
  Role of CHK proteins in cell cycle checkpoint control                            1.29 E --02   E2F4,PPP2R2A,PLK1,PPP2R5C,RAD50,NBN
  Heparan sulfate biosynthesis                                                     1.29 E --02   XYLT1,SULT1A1,HS2ST1,CHST11,EXTL3,HS3ST1
  Heparan sulfate biosynthesis (late stages)                                       2.69 E --02   SULT1A1,HS2ST1,CHST11,EXTL3,HS3ST1
  Nucleotide excision repair pathway                                               3.16 E --02   ERCC1,CDK7,GTF2H2,RAD23B
  Pancreatic adenocarcinoma signaling                                              3.47 E --02   CDKN2A,E2F4,CASP9,MAPK1,PIK3R1,VEGFC,JAK2,NOTCH1
  mTOR signaling                                                                   5.62 E --02   MAPK1,PPP2R2A,RPS27,PIK3R1,PRR5,VEGFC,PPP2R5C,RICTOR,RPS29,PRKCZ,RPS24
  Role of RIG1‐like receptors in antiviral innate immunity                         5.62 E --02   CREBBP,IKBKE,CHUK,TRIM25

  Mode 2 (Dose: 30--150 kJ/m^2^)                                         *P* value     Genes
  ---------------------------------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Molecular mechanisms of cancer                                         8.15 E --03   FYN,RAPGEF1,RELA,RALA,ARHGEF7,PIK3R1,BMP2,PSEN2,CDKN2B,PTK2,CDC25B,NFKBIA,WNT7A,RHOT1,WNT7B,PIK3C3,E2F5,GSK3B,BRCA1,HIPK2,BIRC3,RALGDS,BMP1,PMAIP1,ARHGEF4,PRKCQ,GNA12,RALB,SMAD7,FZD9,MDM2,AURKA,GNAI3,FZD8,FOS,CDKN2D,PRKCI,MAX,CBL,CDKN1A,PRKCH,FNBP1,LRP1
  Factors promoting cardiogenesis in vertebrates                         3.63 E --02   NODAL,PRKCQ,MYL2,TGFBR3,BMP2,FZD9,TCF7L1,FZD8,PRKCI,PRKCH,NPPA,GSK3B,TCF7L2,LRP1,BMP1
  Role of NFAT in regulation of the immune response                      2.14 E --02   RELA,FYN,PRKCQ,CD79B,NFATC3,PIK3R1,CD4,GNA12,CSNK1A1,CD79A,GNAI3,CALM1 (includes others),RCAN1,IKBKB,FOS,CD3G,LCK,NFKBIA,PLCG2,PIK3C3,LAT,ZAP70,LYN,IKBKAP,GSK3B
  NRF2‐mediated oxidative stress response                                1.32 E --02   USP14,PIK3R1,MAF,GCLC,DNAJB2,MAFG,HMOX1,AKR1A1,PIK3C3,DNAJC8,GSK3B,GCLM,GSTM1,PRKCQ,DNAJC19,HERPUD1,JUNB,MAFF,DNAJC21,FOS,PRKCI,ACTA2,PRKCH,MAPK7,DNAJB6,SQSTM1,CDC34,ABCC4
  Fc? receptor‐mediated phagocytosis in macrophages and monocytes        4.68 E --02   FYN,PRKCQ,PIK3R1,INPP5D,MYO5A,PLD4,PLA2G6,HMOX1,CBL,ARPC1A,PRKCI,ACTA2,LYN,PRKCH,ARPC4
  Protein ubiquitination pathway                                         1.70 E --02   USP14,CDC20,HSPB2,HSPA6,DNAJB2,USP2,TCEB1,UBE2F,USP48,USO1,USP8,DNAJC8,USP16,USP47,BRCA1,ANAPC11,BIRC3,NEDD4,USP36,DNAJC19,PSMD6,MDM2,USP1,SKP2,UCHL3,DNAJC21,DNAJC24,CBL,UBE2H,HLA‐C,CUL2,UBE2G1,UBE2E2,CRYAA/LOC102724652,SMURF2,CDC34,DNAJB6
  PKC? signaling in T lymphocytes                                        2.57 E --02   RELA,FYN,PRKCQ,NFATC3,PIK3R1,CD4,MALT1,FOS,IKBKB,CD3G,LCK,NFKBIA,PLCG2,PIK3C3,LAT,ZAP70,MAP3K3,MAP3K2
  CD28 signaling in T helper cells                                       2.57 E --02   RELA,FYN,PRKCQ,NFATC3,CD4,PIK3R1,MALT1,FOS,IKBKB,CALM1 (includes others),CD3G,LCK,ARPC1A,NFKBIA,PIK3C3,LAT,ZAP70,ARPC4
  T cell receptor signaling                                              1.41 E --02   RELA,FYN,PRKCQ,NFATC3,CD4,PIK3R1,MALT1,FOS,IKBKB,CALM1 (includes others),CD3G,LCK,CBL,NFKBIA,PIK3C3,LAT,ZAP70
  Autophagy                                                              1.55 E --04   ATG4C,ATG5,ULK1,VPS18,ATG9A,VPS16,ATG4B,PIK3C3,ATG4A,MAP1LC3B,SQSTM1,VPS11
  Regulation of IL‐2 expression in activated and anergic T lymphocytes   4.47 E --02   IKBKB,FYN,CALM1 (includes others),CD3G,RELA,FOS,NFKBIA,NFATC3,PLCG2,LAT,ZAP70,TOB1,MALT1
  Hereditary breast cancer signaling                                     1.58 E --02   PBRM1,PIK3R1,TUBG1,BARD1,RFC1,DDB2,FANCL,CCNB1,RAD51,BRD7,MSH2,GADD45A,RFC4,SMARCA2,PIK3C3,CDKN1A,XPC,RFC2,BRCA2,BRCA1,RFC3
  p53 signaling                                                          4.07 E --02   PMAIP1,TP53INP1,TOPBP1,PIK3R1,TNFRSF10B,MDM2,TP53I3,SCO2,GADD45A,PIK3C3,ADCK3,CDKN1A,GSK3B,HIPK2,PIDD1,BRCA1
  Cell cycle: G2/M DNA damage checkpoint regulation                      2.69 E --03   CDC25B,GADD45A,YWHAE,CDKN1A,TOP2A,MDM2,AURKA,HIPK2,BRCA1,SKP2,PPM1D,CCNB1
  Role of BRCA1 in DNA damage response                                   2.57 E --04   PBRM1,TOPBP1,BARD1,RBBP8,ATRIP,RFC1,FANCL,RAD51,BRD7,MSH2,RFC4,GADD45A,SMARCA2,CDKN1A,E2F5,RFC2,BRCA2,BRCA1,RFC3
  Purine nucleotides de novo biosynthesis II                             1.38 E --02   ADSS,ADSL,PPAT,ATIC
  Axonal guidance signaling                                              3.52 E --02   FYN,GLI2,MYL2,ITSN1,BDNF,NFATC3,PIK3R1,ARHGEF7,BMP2,PGF,ROCK2,PTK2,SEMA6D,WNT7A,WNT7B,PIK3C3,BAIAP2,NTRK1,ADAM19,PLXNB1,PLXNB2,GSK3B,ERBB2,BMP1,PRKCQ,GNA12,EPHA1,TUBG1,TUBA4A,FZD9,L1CAM,SLIT2,GIT1,GNAI3,FZD8,PRKCI,ARPC1A,TUBB6,PLCG2,EPHB3,PRKCH,ADAM9,OPN1SW,ARPC4,NRP1

Functional Enrichment Analysis {#em22196-sec-0011}
------------------------------

Functional enrichment analysis in BMDExpress Data Viewer applies the Fisher\'s exact test to determine the probability that genes from a particular pathway are over‐represented in a list of DEGs by comparison the complete set of genes in an organism \[Kuo et al., [2016](#em22196-bib-0022){ref-type="ref"}\]. Functional classification of BMDs was conducted for both time‐points as described by Kuo et al. \[[2016](#em22196-bib-0022){ref-type="ref"}\]. The BMD distributions for pathways are provided in Figure [1](#em22196-fig-0001){ref-type="fig"}C. The histogram shows a bimodal response to pathway activation following solar‐simulated UVR exposure. A list of pathways exhibiting a Fisher\'s Exact *P*‐value of ≤ 0.05 with a minimum of five genes is provided in Tables [4](#em22196-tbl-0004){ref-type="table"} and [5](#em22196-tbl-0005){ref-type="table"} for the 6 and 24 hr time‐points, respectively. The pathways were sorted based on BMD values, highlighting those that were perturbed at each mode.

###### 

Statistically Significant Pathways Identified in the 6 hr Time‐Point and Associated BMD Values

  Pathway                                                                           BMD Median unweighted dose (kJ/m^2^)   Fishers exact *P*‐value (%)   Number of significant genes   
  --------------------------------------------------------------------------------- -------------------------------------- ----------------------------- ----------------------------- ------------
  Pyrimidine ribonucleotides interconversion                                        21.7182                                2.13                          6                             **Mode 1**
  Pyrimidine ribonucleotides de novo biosynthesis                                   21.7182                                3.01                          6                             
  Nucleotide excision repair pathway                                                25.98675                               0.5                           8                             
  IGF‐1 signaling                                                                   28.3745                                0.3                           17                            
  DNA double‐strand break repair by homologous recombination                        32.1586                                0.5                           5                             
  Telomere extension by telomerase                                                  37.9528                                0.7                           5                             
  Assembly of RNA polymerase II complex                                             40.5364                                1.81                          9                             
  IL‐15 production                                                                  40.788                                 3.52                          6                             
  Estrogen receptor signaling                                                       41.1082                                0.88                          18                            
  Amyloid processing                                                                48.4955                                3.51                          9                             
  Cell cycle: G2/M DNA damage checkpoint regulation                                 49.1606                                0                             17                            
  Adipogenesis pathway                                                              52.3224                                0.2                           20                            
  Cell cycle control of chromosomal replication                                     54.57425                               0.16                          8                             
  Mitotic roles of polo‐like kinase                                                 57.38095                               0                             15                            **Mode 2**
  Cyclins and cell cycle regulation                                                 60.2006                                0.04                          17                            
  PTEN signaling                                                                    60.2006                                0.05                          21                            
  Cell cycle: G1/S checkpoint regulation                                            60.2006                                0.3                           13                            
  Sonic Hedgehog signaling                                                          61.4501                                3.01                          6                             
  Small cell lung cancer signaling                                                  61.80105                               0.24                          17                            
  Semaphorin signaling in neurons                                                   62.47665                               0.97                          10                            
  mTOR signaling                                                                    63.20475                               0.16                          26                            
  Oxidized GTP and dGTP detoxification                                              63.97375                               0.3                           28                            
  PDGF signaling                                                                    64.06025                               1.67                          12                            
  IL‐17A signaling in fibroblasts                                                   64.1084                                0.36                          9                             
  Prostate cancer signaling                                                         64.4782                                0.98                          16                            
  ERK5 signaling                                                                    65.3988                                0.16                          13                            
  Androgen signaling                                                                65.3988                                0.84                          25                            
  Xenobiotic metabolism signaling                                                   65.4632                                0.08                          37                            
  14‐3‐3‐mediated signaling                                                         66.0496                                0.5                           18                            
  Prolactin signaling                                                               67.1095                                0.03                          16                            
  HIPPO signaling                                                                   67.7237085                             0.09                          16                            
  NGF signaling                                                                     68.1574                                0.06                          20                            
  Antiproliferative role of TOB in T cell signaling                                 68.709575                              2.13                          6                             
  Role of CHK proteins in cell cycle checkpoint control                             68.729567                              0                             15                            
  Cell cycle regulation by BTG family proteins                                      68.729567                              2.82                          7                             
  PI3K/AKT signaling                                                                68.7426835                             0.06                          24                            
  ERK/MAPK signaling                                                                68.7426835                             1.11                          28                            
  Pancreatic adenocarcinoma signaling                                               68.7558                                0.02                          23                            
  Lymphotoxin? receptor signaling                                                   68.7558                                0.05                          13                            
  VEGF family ligand‐receptor interactions                                          68.7558                                0.07                          15                            
  p70S6K signaling                                                                  68.7558                                0.11                          21                            
  Chronic myeloid leukemia signaling                                                68.7558                                0.3                           17                            
  Angiopoietin signaling                                                            68.7558                                0.34                          13                            
  Anti‐inflammation and pro‐apoptotic mechanisms utilized by Yersinia pestis        68.7558                                2.09                          7                             
  G?12/13 signaling                                                                 68.7558                                2.63                          17                            
  UVB‐induced MAPK signaling                                                        68.7558                                3.94                          9                             
  IL‐2 signaling                                                                    68.7558                                3.94                          9                             
  Pyridoxal 5‐phosphate salvage pathway                                             68.7558                                4.13                          23                            
  p53 signaling                                                                     69.5671                                0.02                          20                            
  Fc Epsilon RI signaling                                                           69.95905                               0.13                          18                            
  RAR activation                                                                    70.887025                              0.01                          30                            
  Fc? receptor‐mediated phagocytosis in macrophages and monocytes                   71.1623                                0.18                          17                            
  D‐myo‐inositol (1,4,5)‐trisphosphate degradation                                  71.1623                                1.24                          5                             
  D‐myo‐inositol (1,3,4)‐trisphosphate biosynthesis                                 71.1623                                1.6                           5                             
  1D‐myo‐inositol hexakisphosphate biosynthesis II (Mammalian)                      71.1623                                1.6                           5                             
  Superpathway of D‐myo‐inositol (1,4,5)‐trisphosphate metabolism                   71.1623                                4.37                          5                             
  Docosahexaenoic acid (DHA) signaling                                              71.7331                                1.05                          8                             
  Mechanisms of viral exit from host cells                                          72.60895                               1.7                           8                             
  Ovarian cancer signaling                                                          72.6889                                0.08                          25                            
  Wnt/?‐catenin signaling                                                           73.4417335                             0.29                          26                            
  Transcriptional regulatory network in embryonic stem cells                        73.49585                               1.96                          8                             
  Glioma signaling                                                                  74.8883                                0.16                          20                            
  Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis    75.479                                 0.01                          44                            
  Role of Wnt/GSK‐3? signaling in the pathogenesis of influenza                     75.479                                 3.17                          12                            
  LPS‐stimulated MAPK signaling                                                     76.061                                 0.47                          14                            
  IL‐12 signaling and production in macrophages                                     76.061                                 0.54                          18                            
  IL‐17A signaling in airway cells                                                  76.061                                 1.12                          12                            
  Type II Diabetes mellitus signaling                                               76.061                                 2.34                          20                            
  Effect of Bacillus anthracis toxins on macrophage function                        76.061                                 3.43                          20                            
  HGF signaling                                                                     76.761775                              2.3                           18                            
  PI3K signaling in B lymphocytes                                                   77.26425                               0.02                          24                            
  SAPK/JNK signaling                                                                77.640775                              1.77                          16                            
  Virus entry via endocytic pathways                                                78.16795                               1.72                          14                            
  Filoviral‐mediated alteration of cytokine production in innate immune responses   78.27815                               0.47                          14                            
  Role of pattern recognition receptors in recognition of bacteria and viruses      78.94095                               1.06                          16                            
  VDR/RXR activation                                                                79.41495                               0.63                          14                            
  NRF2‐mediated oxidative stress response                                           79.7547                                0                             37                            
  Gap junction signaling                                                            79.7547                                1.55                          21                            
  CTLA4 signaling in cytotoxic T lymphocytes                                        81.2194                                0.41                          15                            
  eNOS signaling                                                                    81.5021                                2.04                          18                            
  Molecular mechanisms of cancer                                                    81.77585                               0.01                          60                            
  Glucocorticoid receptor signaling                                                 82.2928                                0.01                          42                            
  Glioma invasiveness signaling                                                     82.5309                                4.52                          9                             
  Heparan sulfate biosynthesis                                                      82.7629                                0.27                          24                            
  Heparan sulfate biosynthesis (late stages)                                        82.7629                                0.58                          22                            
  Dopamine‐DARPP32 feedback in cAMP signaling                                       82.8046335                             3.53                          22                            
  Production of nitric oxide and reactive oxygen species in macrophages             82.8388                                0                             30                            
  PPAR signaling                                                                    82.90845                               0.26                          16                            
  Mitochondrial dysfunction                                                         83.3275                                4.86                          19                            
  iNOS signaling                                                                    83.3662                                0.01                          13                            
  B cell receptor signaling                                                         83.3662                                0.09                          27                            
  Antioxidant action of vitamin C                                                   83.3662                                0.1                           15                            
  Induction of apoptosis by HIV1                                                    83.3662                                0.16                          13                            
  IL‐8 signaling                                                                    83.3662                                0.22                          29                            
  Protein Kinase A signaling                                                        83.3662                                0.39                          39                            
  CD27 signaling in lymphocytes                                                     83.3662                                0.59                          11                            
  RANK signaling in osteoclasts                                                     83.3662                                1.15                          15                            
  TWEAK signaling                                                                   83.3662                                2.44                          7                             
  4‐1BB signaling in T lymphocytes                                                  83.46785                               0.61                          8                             
  Cholecystokinin/Gastrin‐mediated signaling                                        83.5016                                4.54                          14                            
  ILK signaling                                                                     83.69635                               0.03                          30                            
  RhoA signaling                                                                    84.63145                               0.54                          18                            
  Role of BRCA1 in DNA damage response                                              84.76775                               0                             21                            
  Hereditary breast cancer signaling                                                84.76775                               0.01                          23                            
  ATM signaling                                                                     84.76775                               0.08                          13                            
  Aryl hydrocarbon receptor signaling                                               84.76775                               0.4                           23                            
  AMPK signaling                                                                    84.76775                               0.46                          27                            
  Tec kinase signaling                                                              84.86515                               1.93                          24                            
  NF‐?B activation by viruses                                                       85.2828                                0.04                          16                            
  G?q signaling                                                                     85.8799                                0.07                          26                            
  April mediated signaling                                                          85.8799                                1.7                           8                             
  IL‐3 signaling                                                                    85.89915                               1.53                          12                            
  Tight junction signaling                                                          86.3458                                2.49                          23                            
  CD40 signaling                                                                    86.4234                                1.12                          12                            
  Insulin receptor signaling                                                        86.4285                                0.13                          21                            
  Role of JAK2 in hormone‐like cytokine signaling                                   86.4285                                1.77                          7                             
  GDNF family ligand‐receptor interactions                                          86.4285                                2.81                          11                            
  Role of osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis         86.43295                               0.6                           30                            
  Systemic lupus erythematosus signaling                                            86.56875                               0.16                          28                            
  CDP‐diacylglycerol biosynthesis I                                                 86.85785                               0.16                          6                             
  Phosphatidylglycerol biosynthesis II (Nonplastidic)                               86.85785                               0.22                          6                             
  NF‐?B signaling                                                                   86.86975                               0.28                          24                            
  T cell receptor signaling                                                         87.1994                                0.01                          21                            
  Natural killer cell signaling                                                     87.1994                                3.32                          15                            
  Hypoxia signaling in the cardiovascular system                                    88.3084                                0.48                          12                            
  Role of NFAT in regulation of the immune response                                 88.3936                                0.01                          31                            
  PKC? signaling in T lymphocytes                                                   88.3936                                0.37                          23                            
  B cell activating factor signaling                                                88.3936                                0.74                          9                             
  Colorectal cancer metastasis signaling                                            89.4806                                0.8                           33                            
  MIF‐mediated glucocorticoid regulation                                            89.4806                                1.49                          7                             
  Estrogen‐mediated S‐phase Entry                                                   89.508075                              1.45                          6                             
  JAK/Stat signaling                                                                89.585875                              3.17                          12                            
  Integrin signaling                                                                89.7925                                2.82                          26                            
  Protein ubiquitination pathway                                                    90.1604                                0                             36                            
  Serotonin degradation                                                             90.3392                                3.98                          10                            
  Breast cancer regulation by Stathmin1                                             90.823725                              1.17                          26                            
  Regulation of IL‐2 expression in activated and Anergic T lymphocytes              91.6453                                0.21                          16                            
  Induction of apoptosis by Francisella tularensis                                  94.3216                                0.41                          15                            
  Erythropoietin signaling                                                          95.8156                                0.13                          14                            
  Sphingosine‐1‐phosphate signaling                                                 96.1025                                0.98                          16                            
  Human embryonic stem cell pluripotency                                            96.431                                 4.74                          21                            
  D‐myo‐inositol (3,4,5,6)‐tetrakisphosphate biosynthesis                           96.8797                                0.01                          43                            
  D‐myo‐inositol (1,4,5,6)‐Tetrakisphosphate biosynthesis                           96.8797                                0.01                          43                            
  3‐phosphoinositide degradation                                                    96.8797                                0.01                          43                            
  3‐phosphoinositide biosynthesis                                                   96.8797                                0.01                          45                            
  Phospholipase C signaling                                                         96.8797                                0.04                          37                            
  Superpathway of inositol phosphate compounds                                      97.9458                                0.01                          48                            
  iCOS‐iCOSL Signaling in T helper cells                                            98.3293                                1.83                          16                            
  MIF regulation of innate immunity                                                 98.8728                                1.7                           8                             
  D‐myo‐inositol‐5‐phosphate metabolism                                             99.0119                                0                             45                            
  Axonal guidance signaling                                                         99.172                                 0.23                          53                            
  Autophagy                                                                         99.25395                               0                             14                            
  p38 MAPK signaling                                                                99.822                                 1.27                          17                            
  Thrombopoietin signaling                                                          99.86325                               0.14                          12                            
  Stearate biosynthesis I (Animals)                                                 100.69505                              1.05                          30                            
  Basal cell carcinoma signaling                                                    100.948                                4.52                          11                            
  Mismatch repair in eukaryotes                                                     101.06645                              0.16                          6                             
  Endothelin‐1 signaling                                                            101.237                                0.63                          22                            
  TREM1 signaling                                                                   102.0385                               3.14                          10                            
  Apoptosis signaling                                                               106.4305                               2.2                           14                            
  Factors promoting cardiogenesis in vertebrates                                    106.848                                0.42                          16                            
  CD28 signaling in T Helper cells                                                  108.265                                0.05                          21                            
  TNFR2 signaling                                                                   108.265                                1.03                          7                             
  Death receptor signaling                                                          108.4875                               0.7                           16                            
  TNFR1 signaling                                                                   108.4875                               0.72                          10                            
  Neuropathic pain signaling in dorsal horn neurons                                 109.432                                2.64                          15                            
  Epithelial adherens junction signaling                                            109.6895                               1.93                          20                            
  Melatonin signaling                                                               111.394                                4.88                          11                            
  Corticotropin releasing hormone signaling                                         111.457                                1.98                          20                            
  Purine nucleotides De Novo biosynthesis II                                        113.154                                0.08                          5                             
  Growth hormone signaling                                                          113.298                                0.64                          13                            
  Oleate biosynthesis II (Animals)                                                  116.092                                1.77                          7                             
  Calcium‐induced T lymphocyte apoptosis                                            116.749                                2.39                          10                            

###### 

Statistically Significant Pathways Identified in the 24 hr Time‐Point and Associated BMD Analysis

  Pathway                                                      BMD Median unweighted dose (kJ/m^2^)   Fishers exact *P*‐value (%)   Number of significant genes   
  ------------------------------------------------------------ -------------------------------------- ----------------------------- ----------------------------- ------------
  Pyrimidine deoxyribonucleotides de novo biosynthesis I       19.3256                                0                             8                             **Mode 1**
  Pyrimidine ribonucleotides interconversion                   19.3923                                3.72                          5                             
  Pyrimidine ribonucleotides de novo biosynthesis              19.3923                                4.93                          5                             
  Methionine degradation I (to Homocysteine)                   19.5567                                0.03                          13                            
  Cysteine biosynthesis III (mammalia)                         19.5567                                0.04                          13                            
  Superpathway of methionine degradation                       19.5567                                0.17                          13                            
  Autophagy                                                    28.7172                                1.39                          7                             
  Superpathway of cholesterol biosynthesis                     30.2143                                1.16                          6                             
  Role of Oct4 in mammalian embryonic stem cell pluripotency   30.304                                 1.5                           8                             
  GADD45 signaling                                             34.8245                                1                             5                             
  ATM signaling                                                37.6877                                0.06                          12                            
  Triacylglycerol biosynthesis                                 42.8107                                0.54                          15                            **Mode 2**
  Glutaryl‐CoA degradation                                     42.8107                                0.82                          9                             
  p53 signaling                                                45.029                                 2.93                          13                            
  Small cell lung cancer signaling                             51.444075                              4.26                          12                            
  Estrogen‐mediated S‐phase Entry                              55.7718                                2.71                          5                             
  Pancreatic adenocarcinoma signaling                          55.7718                                2.83                          15                            
  Role of CHK Proteins in cell cycle checkpoint control        58.0174                                0                             14                            
  Cell cycle control of chromosomal replication                58.82865                               0.05                          8                             
  Mismatch repair in eukaryotes                                60.263                                 0.45                          5                             
  Role of BRCA1 in DNA damage response                         60.263                                 0.62                          11                            
  Hereditary breast cancer signaling                           61.87215                               0.13                          18                            
  Tryptophan degradation III (Eukaryotic)                      65.0471                                0.76                          10                            
  Ovarian cancer signaling                                     68.27525                               4.93                          17                            
  Cell cycle: G2/M DNA damage checkpoint regulation            71.9505                                0                             16                            
  Bladder cancer signaling                                     74.4811                                0.04                          18                            
  Stearate biosynthesis I (Animals)                            75.53915                               0.09                          30                            
  Signaling by Rho family GTPases                              76.6873                                4.68                          26                            
  Amyotrophic lateral sclerosis signaling                      82.84405                               2.22                          14                            
  Axonal guidance signaling                                    83.8447                                3.32                          41                            
  Pyridoxal 5‐phosphate salvage pathway                        85.6785                                1.18                          22                            
  Cell cycle: G1/S checkpoint regulation                       86.711125                              2.47                          10                            
  Salvage pathways of pyrimidine ribonucleotides               87.4168                                0.15                          27                            
  Endothelin‐1 signaling                                       91.03745                               2.11                          18                            
  Cyclins and cell cycle regulation                            92.25125                               0                             18                            
  Mitotic roles of polo‐like kinase                            94.0146                                0                             21                            
  Remodeling of epithelial adherens junctions                  94.7878                                3.77                          9                             
  Adipogenesis pathway                                         95.9394                                0.98                          16                            
  Eicosanoid signaling                                         97.73305                               1.15                          8                             
  ILK signaling                                                98.95675                               1.18                          22                            
  Phospholipases                                               99.41165                               0.25                          10                            
  Inhibition of matrix metalloproteases                        104.7145                               0.53                          8                             
  Ubiquinol‐10 biosynthesis (eukaryotic)                       106.365                                1.69                          17                            
  Telomerase signaling                                         108.175                                4.48                          12                            
  Melatonin degradation I                                      110.125                                4.66                          9                             
  Glycolysis I                                                 111.4                                  2.71                          5                             

In general, solar‐simulated UVR exposure induced pathways involved in nucleotide metabolism, cell cycle control, cell signaling, DNA damage response, and apoptosis. This response was consistent at both time‐points after exposure, but was somewhat attenuated at 24 hr postexposure (data not shown). Twenty‐four pathways and 468 probes were common between the two time‐points (data not shown). Unique pathways and probes were also identified between the two time‐points; however, no further analysis was conducted on these datasets. BMD median values for the common pathways were generally higher for the 6 hr postexposure time‐point (Table [6](#em22196-tbl-0006){ref-type="table"}). Seven out of the 24 genes demonstrated BMD median values that were higher for the 24 hr time‐point relative to the 6 hr time‐point. These genes were mostly involved in cell cycle regulation, cell differentiation, or cell signaling. Functional Enrichment Analysis of Fisher Exact *P*‐values (≤ 0.05) vs BMD median values was used to identify pathways that were potentially important for the mode of action of solar‐simulated UVR exposure (Supporting Information Table S2). This analysis identified pathways related to molecular mechanisms of cancer and axonal guidance signaling, with BMD median values between 81 and 99 kJ/m^2^, to be the most responsive to solar simulated UVR. The same two pathways were also sustained at 24 hr postexposure (data not shown). The lowest pathway BMD in the overall dataset was pyrimidine deoxyribonucleotide de novo biosynthesis I, with a BMD of 19.3 kJ/m^2^, and eight genes with BMDs at 24 hr.

###### 

Common Pathways Between 6 and 24 hr and Associated BMD Values

                                                          BMD median unweighted dose (kJ/m^2^)   
  ------------------------------------------------------- -------------------------------------- -----------
  Pyrimidine ribonucleotides de novo biosynthesis         21.7182                                19.3923
  Pyrimidine ribonucleotides interconversion              21.7182                                19.3923
  Cell Cycle: G2/M DNA damage checkpoint regulation       49.1606                                71.9505
  Adipogenesis pathway                                    52.3224                                95.9394
  Cell cycle control of chromosomal replication           54.57425                               58.82865
  Mitotic roles of polo‐like kinase                       57.38095                               94.0146
  Cell Cycle: G1/S checkpoint regulation                  60.2006                                86.711125
  Cyclins and cell cycle regulation                       60.2006                                92.25125
  Small cell lung cancer signaling                        61.80105                               51.444075
  Role of CHK proteins in cell cycle checkpoint control   68.729567                              58.0174
  Pancreatic adenocarcinoma signaling                     68.7558                                55.7718
  Pyridoxal 5‐phosphate salvage pathway                   68.7558                                85.6785
  p53 signaling                                           69.5671                                45.029
  Ovarian cancer signaling                                72.6889                                68.27525
  ILK signaling                                           83.69635                               98.95675
  ATM signaling                                           84.76775                               37.6877
  Role of BRCA1 in DNA damage response                    84.76775                               60.263
  Hereditary breast cancer signaling                      84.76775                               61.87215
  Estrogen‐mediated S‐phase Entry                         89.508075                              55.7718
  Axonal guidance signaling                               99.172                                 83.8447
  Autophagy                                               99.25395                               28.7172
  Stearate biosynthesis I (Animals)                       100.69505                              75.53915
  Mismatch repair in eukaryotes                           101.06645                              60.263
  Endothelin‐1 signaling                                  101.237                                91.03745

DISCUSSION {#em22196-sec-0012}
==========

With the advent of genomic technologies, the throughput of detecting molecular changes has dramatically increased employing bioinformatic techniques to predict precursors of more profound biological changes. Recent papers suggest that the application of BMD modeling to transcriptional data offers significant advantages over traditional genomic bioinformatics approaches \[Farmahin et al., [2017](#em22196-bib-0013){ref-type="ref"}\]. BMD modeling of transcriptomic data provides more quantitative information on threshold gene and pathway responses (e.g., point‐of‐departure), simpler interpretation of large datasets, and allows direct comparison to other data with similar endpoints without the need to have matched doses to increase threshold prediction accuracy \[Webster et al., [2015](#em22196-bib-0035){ref-type="ref"}\]. In this study, we present the first analysis of gene responsiveness to solar‐simulated UVR using BMD modeling.

BMD modeling requires experimental data at a minimum of three doses across a broad range. In our test example, keratinocytes were exposed to a low, medium or high dose of UVR (0, 10, 20, 150 kJ/m^2^). At 6 and 24 hr postexposure, cells were harvested and assessed for transcriptional changes using BMD modeling. The data displayed a bi‐modal distribution at both 6 and 24 hr postexposure for both individual transcripts and pathways. The majority of the transcripts demonstrated a linear trend‐line, implying that solar‐simulated UVR exposure induced a dose‐responsive change in gene expression. For both time‐points the median BMD values for Modes 1 and 2 were ∼16 kJ/m^2^ and ∼108 kJ/m^2^, respectively. Although the meaning of this bi‐modal response is unclear, this finding is consistent with our previous analysis of BMD responses using ionizing radiation (X‐rays and alpha particles) \[Chauhan et al., [2016](#em22196-bib-0008){ref-type="ref"}\]. It is likely that these modes reflect different mechanisms and toxicological effects that are being induced at different doses, and should thus provide meaningful insight in the effects of the exposure. To explore this in more detail, we performed pathway analysis of genes observed within each mode.

At 6 hr postexposure in Mode 1 (3--27 kJ/m^2^) we observed transcriptional changes in cell cycle regulation pathways, presumably associated with induction of DNA repair mechanisms. Studies have shown that within this dose range, cells have capacity to repair damage without leading to propagation of gross morphological damage \[Pontén et al., [1995](#em22196-bib-0028){ref-type="ref"}; Young et al., [1996](#em22196-bib-0037){ref-type="ref"}, [1998](#em22196-bib-0038){ref-type="ref"}; Heenen et al., [2001](#em22196-bib-0015){ref-type="ref"}; Chang et al., [2003](#em22196-bib-0007){ref-type="ref"}; Huang et al., [2013](#em22196-bib-0016){ref-type="ref"}\]. With higher doses of UVR (Mode 2), we observed transcriptional changes in DNA repair pathways, but also the activation of pathways related to cancer development, suggesting that above this dose there is a transition to perturbations in transcripts involved in a variety of processes and functions that are altered in cancer cells. This is also reflected in transcriptional changes in pathways associated with activation of cellular apoptosis and immune response. At 24 hr postexposure, a similar bi‐modal response was observed, supporting the mechanism‐based information derived from the modal analysis.

At 24 hr postexposure in Mode 1 (2--27 kJ/m^2^), transcriptionally activated pathways were predominately associated with nucleotide biosynthesis, with a few effectors involved in cell cycle signaling. At the higher dose range (Mode 2), pathways involved in cell signaling and cell cycle regulation were activated, while cancer‐promoting pathways were also still prominent. Interestingly, we also observed that genes involved in DNA repair pathways were transcriptionally altered, indicating that the DNA damage response persisted despite the long postexposure incubation time, possibly resulting from UVA‐induced DNA damage. It has been shown that repair mechanisms for UVA are less efficient and that the damage may persist several hours after exposure \[Tadokoro et al., [2003](#em22196-bib-0031){ref-type="ref"}; Agar and Young, [2005](#em22196-bib-0001){ref-type="ref"}\].

Twenty‐four pathways in both modes at the 24 hr time point were also found in the 6 hr time point in the same modes (Table [6](#em22196-tbl-0006){ref-type="table"}). These pathways involved DNA damage recognition, pyrimidine metabolism, and cell cycle regulation. Interestingly, some unexpected pathways also appeared to be common across the two time‐points, including endothelin signaling and axonal guidance signaling at the higher dose range (Mode 2). These responses are consistent with previous publications demonstrating that UVR exposure can cause activation of mutagenic repair dimers, recombination repair, and cell‐cycle checkpoint regulation and apoptosis, as activated through the ATR kinase pathway \[Brown and Baltimore, [2003](#em22196-bib-0005){ref-type="ref"}\]. A comparison of the BMD medians for these pathways showed the majority to have lower BMD values for the 24 hr time‐point relative to the 6 hr time‐point, possibly highlighting a time‐dependency in pathway activation.

Li et al. \[[2001](#em22196-bib-0023){ref-type="ref"}\] reported time‐dependency of UVB‐induced gene expression changes as they observed three waves involving early (0.5--2 hr), intermediate (4--8 hr), and late (16--24 hr) stages of gene expression. Early expression changes were associated with transcription factors such as c‐myc and c‐fos, mitochondrial proteins like cytochromes c and b, and changes in phosphorylation states with altered expression of either kinases or phosphatases, responding to the immediate damage. Whereas, cytokines, chemokines, and growth factors dominated the intermediate wave, particularly the neutrophil chemotactic and melanocyte activator interleukin 8, most of which are involved in the erythemal process. Genes induced at the late stage were predominately differentiation markers involved in the protective cornified envelope of the skin.

Human maximum permissible exposure (MPE) limits for UVR (by wavelength) have been previously developed for both the eye and skin by the International Commission on Non‐Ionizing Radiation Protection \[ICNIRP, [2004](#em22196-bib-0017){ref-type="ref"}\]. These MPE\'s have been implemented by the International Electrotechnical Commission (IEC) in their standard IEC‐62471 (2006) "Photobiological safety of lamps and lamp systems" to establish an actinic exposure limit for broadband UVR (200 to 400 nm) for unprotected skin and the eye for an 8 hr period of 0.03 kJ/m^2^(erythemally‐weighted). It is interesting to note that the median from Mode one, found in the current study, coincided with the ICNIRP MPE limit.

Previous studies have shown cellular responses can occur at exposure levels below the MPE limit. Pontén et al. \[[1995](#em22196-bib-0028){ref-type="ref"}\] demonstrated upregulated expression of p53 and p21 in an *in vivo* study using broadband UVR at a dose of ∼0.03 kJ/m^2^ as soon as 4 hr post exposure. Similarly, Huang et al. \[[2013](#em22196-bib-0016){ref-type="ref"}\] reported an increase in nuclear p53 in keratinocytes at 3 hr postexposure to ∼0.03 kJ/m^2^ as a result of oxidative stress with minor cytotoxicity. The authors postulated that p53 played a role as a transcriptional repressor by downregulating a number of proteins that may result in photo‐aging effects. Interestingly, in this study, we found that the median of Mode 1 response corresponded to a dose of ∼0.03 kJ/m^2^ (unweighted UVR irradiance of ∼16 kJ/m^2^). The probes/pathways expressed at this dose were involved in cell signaling and DNA damage response, despite the lack of effect on apoptosis or decline in cellular viability (data not shown). Overall, our data show that stressor signaling in keratinocytes occurred at the actinic exposure limit (8 hr) of international standards designed to limit acute adverse effects (e.g., erythema).

Small increases in the exposure level above the actinic exposure limit (0.03 kJ/m^2^) have been reported to initiate dramatic cellular responses. Eberlein‐König et al. \[[1998](#em22196-bib-0011){ref-type="ref"}\] reported that exposure to UVB (0.05 kJ/m^2^, erythemally‐weighted) was able to significantly increase the inflammatory cytokines IL‐1α and IL‐6 24 hr postirradiation. At 0.1 kJ/m^2^ UVR (erythemally‐weighted), Köck et al. \[[1990](#em22196-bib-0021){ref-type="ref"}\] showed UVR could initiate the release of the inflammatory and pro‐apoptotic cytokine TNF‐α from human keratinocytes. Similarly, other studies have found that UVR can induce apoptosis and cellular death in keratinocytes in this dose range \[Chang et al., [2002](#em22196-bib-0006){ref-type="ref"}, [2003](#em22196-bib-0007){ref-type="ref"}; Kang et al., [2011](#em22196-bib-0020){ref-type="ref"}\]. In the current study, the median BMD value for Mode 2 (∼108 kJ/m^2^ unweighted, ∼0.184 kJ/m^2^ erythemally‐weighted) coincided with the dose required to cause minimal erythema to an individual with a type I fair skin type (0.2 kJ/m^2^ = 1 Minimum Erythemal Dose (MED) or 2 Standard Erythemal Dose (SED)).

This preliminary work shows the potential of BMD modeling of transcriptional data to support point‐of‐departure assessment of molecular responses to UVR exposure. Although promising, additional studies/datasets are required to assess a larger assortment of dose ranges, exposure conditions, time‐lines and cell lines/tissues to ensure the consistency of the results prior to comparison of thresholds derived from conventional methods to current exposure limits to UVR. In addition, the current BMD methodology used for chemical risk assessment, which is at more advanced stages of implementation, may need to be refined for its appropriate applicability to UVR exposure. The additional value is that genomic data from any study with similar experimental procedures can be added to the analysis building on the weight of evidence with mechanistic data to support decision‐making. In all, the study suggests a potential use of BMD modeling of transcriptome data to determine biologically‐relevant thresholds of UVR responses.
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